Alzheimer's Disease Trial, Recruiting NCT06492109 Sponsor: First Affiliated Hospital of Zhejiang University Condition: Alzheimer's Disease
Back to Alzheimers Disease

Alzheimer's Disease Trial, Recruiting

NCT06492109
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are willing and able to sign a consent form agreeing to take part in the study.
  • People who meet the specific requirements for the particular group (arm) of the trial they are being considered for (confirm with trial site).

Who may not be able to join:

  • People who are not willing or able to provide signed consent to participate.
  • People who may have difficulty following the study's procedures due to language differences or problems with memory or thinking.
  • People who regularly take certain medications that may affect sleep, such as opioid pain medicines, benzodiazepines (a type of sedative), or non-benzodiazepine sleeping tablets (sometimes called Z drugs).
  • People with a history of alcohol misuse, drug misuse, loss of consciousness, stroke or other blood vessel problems in the brain, head injury, epilepsy, brain infections, or other nervous system conditions.
  • People who have been diagnosed with schizophrenia, severe depression, severe anxiety disorders, or other serious mental health conditions.
  • People who have serious heart rhythm problems, a heart attack within the last 6 months, severe lung problems, kidney or liver failure, severe anaemia, severe digestive system diseases, cancer, or other serious health conditions.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 9 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Benyan Luo, Zhejiang University

Phone: 0571-87236537

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
First Affiliated Hospital of Zhejiang University
Registry
ClinicalTrials.gov
Start date
20 June 2024
Est. completion
31 December 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Hamilton Anxiety Rating Scale (HAM-A); Hamilton Depression Rating Scale (HDRS); Mini-Mental State Examination (MMSE); Montreal Cognitive Assessment (MoCA); Transcriptomic profile; Metabolic profiling; Self reported scales

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 9 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov